Search Result

Results for "

CT-26

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (4) AUTACs (1) Autophagy (3) Caspase (1) CDK (1) Cytochrome P450 (1) Fungal (2) Indoleamine 2,3-Dioxygenase (IDO) (2) Integrin (1) Interleukin Related (1) Keap1-Nrf2 (1) Liposome (1) MAGL (1) MAP4K (2) NAMPT (1) NF-κB (1) p38 MAPK (1) PD-1/PD-L1 (4) Phosphodiesterase (PDE) (1) PI3K (1) Platelet-activating Factor Receptor (PAFR) (1) Prostaglandin Receptor (2) PROTACs (1) Reactive Oxygen Species (1) SHP2 (2) STING (1) β-catenin (1)
By Research Areas:	Cancer (23) Infection (2) Inflammation/Immunology (8) Neurological Disease (1)

By Targets:

Akt (1)

Apoptosis (4)

AUTACs (1)

Autophagy (3)

Caspase (1)

CDK (1)

Cytochrome P450 (1)

Fungal (2)

Indoleamine 2,3-Dioxygenase (IDO) (2)

Integrin (1)

Interleukin Related (1)

Keap1-Nrf2 (1)

Liposome (1)

MAGL (1)

MAP4K (2)

NAMPT (1)

NF-κB (1)

p38 MAPK (1)

PD-1/PD-L1 (4)

Phosphodiesterase (PDE) (1)

PI3K (1)

Platelet-activating Factor Receptor (PAFR) (1)

Prostaglandin Receptor (2)

PROTACs (1)

Reactive Oxygen Species (1)

SHP2 (2)

STING (1)

β-catenin (1)

By Research Areas:

Cancer (23)

Infection (2)

Inflammation/Immunology (8)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10439

CVRARTR	PD-1/PD-L1	Cancer
CVRARTR is an antagonist for programmed cell death ligand-1 (PD-L1) with K_D of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model .

HY-155971

VISTA-IN-2	Autophagy	Inflammation/Immunology Cancer
VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .

HY-155457

Enpp-1-IN-19	Phosphodiesterase (PDE) STING	Cancer
Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC₅₀=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence .

HY-169239

MAGL-IN-20	MAGL	Cancer
MAGL-IN-20 (compound ±34) is a reversible monoacylglycerol lipase (MAGL) inhibitor. MAGL-IN-20 exhibits appreciable antiproliferative activities against several cancer cells, including H460, HT29, CT-26, Huh7 and HCCLM-3. .

HY-139716

IMD-catechol	NF-κB	Inflammation/Immunology
IMD-catechol is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.

HY-169918

SHP2-IN-34	SHP2	Cancer
SHP2-IN-34 (compound A8) is a phenyl urea SHP2 inhibitor with anti-cancer activity. SHP2-IN-34 significantly suppresses tumor growth in CT26 mouse model .

HY-172453

XW-032	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
XW-032 is an apo-IDO1 inhibitor, with an IC₅₀ of 21 nM. XW-032 (TGI = 63%) exhibits potent in vivo anti-tumor efficacy in the CT26 syngeneic mouse model and is expected to be applied in the research of the field of cancer .

HY-162766

Antitumor agent-184	Apoptosis	Cancer
Antitumor agent-184 (compound 12aa) induces cell apoptosis, with the IC₅₀s of 2.35 μM, 7.32 μM and 10.31 μM in B16-F10 cells, 4T1 cells and CT26 cells, respectively .

HY-N7484

(−)-Voacangarine	Fungal	Cancer
(−)-Voacangarine is an indole alkaloid, which exhibits cytotoxic effects against cancer cells HepG2, A375, MDA-MB-231, SH-SY5Y, and CT26 with IC₅₀ of 5~20 mg/mL. (−)-Voacangarine inhibits the cultivation of Saccharomyces cerevisiae wildtype and repair-deficient mutants .

HY-164360

αVβ8-IN-1	Integrin	Inflammation/Immunology Cancer
αVβ8-IN-1 is a αVβ8 integrin inhibitor. αVβ8-IN-1 has been shown to inhibit the growth of tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 can be used in research related to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and tumors .

HY-132192

PD-1/PD-L1-IN-9 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-132192A

PD-1/PD-L1-IN-9 hydrochloride 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-172209

PPIA-IN-1	p38 MAPK Apoptosis Reactive Oxygen Species	Cancer
PPIA-IN-1 (Compound 20b) is the inhibitor for peptidylprolyl isomerase A (PPIA) with a K_D of 0.52 μM. PPIA-IN-1 exhibits antiproliferative activity in a variety of cancer cell lines (IC₅₀ for HCT116 is 0.69 μM), arrests the cell cycle at G0/G1 phase, and exhibits anti-metastatic effect in cell HCT116. PPIA-IN-1 increases ROS, causes DNA damage, ER stress and mitochondrial dysfunction, inducing apoptosis in HCT116 through MAPK pathway. PPIA-IN-1 exhibits antitumor activity in mouse CT26 xenograft models .

HY-170877

SHP2-IN-35	SHP2 PI3K Akt Autophagy	Cancer
SHP2-IN-35 (Compound 3f) is the inhibitor for SHP2. SHP2-IN-35 exhibits antiproliferative activity in cancer cells RKO, SW480 and CT26 with IC₅₀ of 5.72 μM, 3.71 μM and 1.42 μM, respectively. SHP2-IN-35 inhibits the PI3K-Akt signaling pathway, regulates the cell cycle associated gene expressions, and induces mitochondrial-related autophagy. SHP2-IN-35 inhibits the expression of certain cytokines and chemokines in the tumor microenvironment (TME), thereby regulating the tumor progression .

HY-159905

HPK1-IN-54	MAP4K	Inflammation/Immunology
HPK1-IN-54 is a potent HPK1 (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting HPK1 activity, thereby exhibiting antitumor effects. Its IC₅₀ value against HPK1 is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy .

HY-169363

PDL1 degrader-2	PD-1/PD-L1 Autophagy AUTACs	Cancer
PD-L1 degrader-2 (Compound B3) is an orally active AUTAC degrader, that degrades PD-L1 through autophagy-lysosome pathway with a DC₅₀ of 0.5 μM. PD-L1 degrader-2 exhibits inhibitory activity against PD-1/PD-L1 interaction with an IC₅₀ of 22.8 nM. PD-L1 degrader-2 upregulates the expressions of Atg9b, Lamp1 and Mitf, and activates the autophagy lysosome system. PD-L1 degrader- exhibits antitumor efficacy in CT26 mouse model . (Pink: autophagy-lysosome activator (HY-159894); Black: linker (HY-W015088); Blue: PD-L1 ligand (HY-169365))

HY-169480

Lipid C2	Liposome	Infection Cancer
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .

HY-169859

EP4 receptor antagonist 7	Prostaglandin Receptor Interleukin Related	Inflammation/Immunology Cancer
EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC₅₀ value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC₅₀ value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD ⁸⁺ T cells into tumors in a CT26 murine colon cancer model .

HY-162537

LYP-8	PROTACs NAMPT	Cancer
LYP-8 is a potent and effective NAMPT degrader with maximum degradation of 97% at 0.5 μM in SKOV-3 cells. LYP-8 shows anti-cancer activity in vivo and in vitro(Sturcture Note:(Blue: Cereblon ligand (HY-112078), Black: linker (HY-128801)；Pink: Nampt inhibitor Nampt-IN-11 (HY-158689)) .

HY-149290

AMX12006	Prostaglandin Receptor	Cancer
AMX12006 is a potent, selective and orally active EP4 antagonist with an IC₅₀ value of 4.3 nM. AMX12006 shows cytotoxic and antitumor activity .

HY-151463A

CDK8-IN-11 hydrochloride	CDK β-catenin	Cancer
CDK8-IN-11 hydrochloride is a potent and selective CDK8 inhibitor with an IC₅₀ value of 46 nM. CDK8-IN-11 hydrochloride inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 hydrochloride can be used in the research of colon cancer .

HY-149773S

HPK1-IN-40-d2	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC₅₀ of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity .

HY-N2071

Cedrol 1 Publications Verification (+)-Cedrol; α-Cedrol	Cytochrome P450 Fungal Apoptosis Caspase Platelet-activating Factor Receptor (PAFR)	Infection Neurological Disease Inflammation/Immunology Cancer
Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties .

HY-151425

TDO-IN-1	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC₅₀ value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo .

HY-19543

Brusatol Maximum Cited Publications 32 Publications Verification NSC 172924	Keap1-Nrf2 Apoptosis	Cancer
Brusatol (NSC?172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent . Brusatol increases cellular apoptosis .

Cat. No.	Product Name	Target	Research Area